Drugs / RTX-134
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04110496 | Jan 2020 → Dec 2022 | phenylketonuria | Rubius Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTX-134 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04110496 ↗ |
| Modality | Cell therapy | “RTX-134 is a cellular therapy containing AvPAL” NCT04110496 ↗ |
| Route | Intravenous | “following intravenous administration of a single dose” NCT04110496 ↗ |